Abstract
Abstract: Atherosclerosis is a systemic diffuse disease that may manifest as an anglographically localized coronary, cerebral, mesenteric, renal, and/or peripheral arterial stenosis or as diffuse atherosclerosis. While relief of organ ischemia is frequently possible with percutaneous or surgical revascularization, this in itself does not alleviate the long-term risks of disease recurrence or modify the metabolic derangements that promote atherosclerosis. It is critically important to recognize the need for treatment of dyslipidemia and to institute necessary therapies. The complex role of lipoprotein abnormalities is well understood and the use of lipid-lowering agents (90% statins) is reviewed in both primary and secondary prevention. The clinical interaction with novel risk factors and the practical problems in patient management are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 445-486 |
| Number of pages | 42 |
| Journal | Current Problems in Cardiology |
| Volume | 31 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2006 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Pathophysiology, Diagnosis, and Management of Dyslipidemia. / Gau, Gerald T.; Wright, R. Scott.
In: Current Problems in Cardiology, Vol. 31, No. 7, 01.07.2006, p. 445-486.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pathophysiology, Diagnosis, and Management of Dyslipidemia
AU - Gau, Gerald T.
AU - Wright, R. Scott
PY - 2006/7/1
Y1 - 2006/7/1
N2 - Abstract: Atherosclerosis is a systemic diffuse disease that may manifest as an anglographically localized coronary, cerebral, mesenteric, renal, and/or peripheral arterial stenosis or as diffuse atherosclerosis. While relief of organ ischemia is frequently possible with percutaneous or surgical revascularization, this in itself does not alleviate the long-term risks of disease recurrence or modify the metabolic derangements that promote atherosclerosis. It is critically important to recognize the need for treatment of dyslipidemia and to institute necessary therapies. The complex role of lipoprotein abnormalities is well understood and the use of lipid-lowering agents (90% statins) is reviewed in both primary and secondary prevention. The clinical interaction with novel risk factors and the practical problems in patient management are discussed.
AB - Abstract: Atherosclerosis is a systemic diffuse disease that may manifest as an anglographically localized coronary, cerebral, mesenteric, renal, and/or peripheral arterial stenosis or as diffuse atherosclerosis. While relief of organ ischemia is frequently possible with percutaneous or surgical revascularization, this in itself does not alleviate the long-term risks of disease recurrence or modify the metabolic derangements that promote atherosclerosis. It is critically important to recognize the need for treatment of dyslipidemia and to institute necessary therapies. The complex role of lipoprotein abnormalities is well understood and the use of lipid-lowering agents (90% statins) is reviewed in both primary and secondary prevention. The clinical interaction with novel risk factors and the practical problems in patient management are discussed.
UR - http://www.scopus.com/inward/record.url?scp=33745638548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745638548&partnerID=8YFLogxK
U2 - 10.1016/j.cpcardiol.2006.03.001
DO - 10.1016/j.cpcardiol.2006.03.001
M3 - Article
C2 - 16824902
AN - SCOPUS:33745638548
VL - 31
SP - 445
EP - 486
JO - Current Problems in Cardiology
JF - Current Problems in Cardiology
SN - 0146-2806
IS - 7
ER -